Oncology
1 drug is in development for Endometrial Carcinoma.
- Companies
- 1
- Clinical trials
- 12
BioSniper AIPage evidence connected
Prepared research question
Which programs lead the Endometrial Carcinoma pipeline—and what evidence could change the picture?
Run cited research
Traceable citations · Unknowns marked
Drug Pipeline by Phase
Phase 1(1)
| Drug | Company |
|---|---|
| FT836 | FATE THERAPEUTICS INC (FATE) |
About this indication
Endometrial Carcinoma context
Oncology·MeSH: Endometrial Neoplasms (D016889)
Narrower concept of MeSH descriptor Endometrial Neoplasms
Prevalence
58.0 / 100K
Incidence
28.0 / 100K/yr
Frequently asked questions
How many drugs are in development for Endometrial Carcinoma?
BioSniper tracks 1 drug in development for Endometrial Carcinoma across 1 company.
How many clinical trials target Endometrial Carcinoma?
There are 12 clinical trials targeting Endometrial Carcinoma tracked by BioSniper.
What is the prevalence of Endometrial Carcinoma?
The estimated prevalence of Endometrial Carcinoma is approximately 58.0 per 100,000 population.